All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

durvalumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
human origin	5234	1428935-60-7

Description:

Molecule

Description

Synonyms: durvalumab MEDI4736 MEDI 4736 imfinzi durvalumab (genetical recombination)

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, without inducing antibody dependent cellmediated cytotoxicity (ADCC). PD-L1 blockade with durvalumab led to increased T-cell activation in vitro and decreased tumor size in co-engrafted human tumor and immune cell xenograft mouse models. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
53.60	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Sept. 21, 2018	EMA	ASTRAZENECA AB
July 2, 2018	PMDA	AstraZeneca KK
May 1, 2017	FDA	ASTRAZENECA UK LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	745.12	31.13	310	8888	106560	90512689
Radiation pneumonitis	655.67	31.13	120	9078	1738	90617511
Death	455.07	31.13	372	8826	456179	90163070
Pneumonitis	439.46	31.13	166	9032	44004	90575245
Cholangitis	188.02	31.13	56	9142	7126	90612123
Metastases to central nervous system	181.72	31.13	68	9130	17474	90601775
Biliary tract infection	181.63	31.13	36	9162	808	90618441
Neutrophil count decreased	159.56	31.13	96	9102	71436	90547813
Immune-mediated enterocolitis	150.62	31.13	43	9155	4714	90614535
Hypothyroidism	149.64	31.13	83	9115	53044	90566205
Colitis	146.07	31.13	90	9108	69852	90549397
Myocarditis	137.47	31.13	52	9146	13754	90605495
Myelosuppression	127.50	31.13	75	9123	53516	90565733
Immune-mediated hepatitis	108.62	31.13	30	9168	2914	90616335
Liver abscess	103.52	31.13	30	9168	3466	90615783
Febrile neutropenia	97.44	31.13	99	9099	158250	90460999
Immune-mediated lung disease	97.11	31.13	25	9173	1855	90617394
Cholangitis infective	95.03	31.13	19	9179	446	90618803
Immune-mediated myocarditis	90.30	31.13	22	9176	1303	90617946
Thyroiditis	89.30	31.13	27	9171	3610	90615639
Interstitial lung disease	85.43	31.13	67	9131	76338	90542911
Platelet count decreased	83.09	31.13	85	9113	136884	90482365
Anaemia	81.85	31.13	136	9062	352666	90266583
Pyrexia	81.16	31.13	195	9003	660290	89958959
Immune-mediated hepatic disorder	74.21	31.13	20	9178	1772	90617477
Embolism	74.20	31.13	30	9168	9451	90609798
Tumour hyperprogression	73.07	31.13	13	9185	158	90619091
Pemphigoid	72.15	31.13	29	9169	8997	90610252
Hepatic function abnormal	70.70	31.13	49	9149	46239	90573010
Urinary tract obstruction	69.71	31.13	20	9178	2229	90617020
Cytokine release syndrome	68.73	31.13	40	9158	27933	90591316
Bile duct stenosis	65.41	31.13	18	9180	1724	90617525
Hyperthyroidism	63.85	31.13	33	9165	18277	90600972
Bacterial abdominal infection	62.64	31.13	9	9189	22	90619227
Myasthenia gravis	61.81	31.13	24	9174	6801	90612448
Pleural effusion	61.62	31.13	66	9132	111925	90507324
Nephritis	58.69	31.13	19	9179	3176	90616073
Drug-induced liver injury	58.30	31.13	58	9140	90260	90528989
Metastatic malignant melanoma	57.39	31.13	16	9182	1608	90617641
Metastases to liver	57.37	31.13	36	9162	28771	90590478
Neoplasm progression	56.26	31.13	42	9156	44444	90574805
Small intestinal obstruction	53.85	31.13	31	9167	21203	90598046
Haematotoxicity	53.76	31.13	26	9172	12509	90606740
Immune-mediated hypothyroidism	53.46	31.13	15	9183	1543	90617706
Metastases to lung	53.40	31.13	28	9170	15963	90603286
Arterial intramural haematoma	53.30	31.13	10	9188	166	90619083
Pulmonary toxicity	52.74	31.13	25	9173	11506	90607743
Immune-mediated adverse reaction	52.10	31.13	13	9185	850	90618399
Adrenal insufficiency	51.22	31.13	34	9164	29887	90589362
Immune-mediated myositis	51.08	31.13	16	9182	2405	90616844
Type 1 diabetes mellitus	51.07	31.13	19	9179	4793	90614456
Liver carcinoma ruptured	49.59	31.13	8	9190	51	90619198
Metastases to bone	48.60	31.13	31	9167	25474	90593775
Thrombophlebitis migrans	48.60	31.13	10	9188	272	90618977
Neuropathy peripheral	47.76	31.13	64	9134	136906	90482343
Polyneuropathy	45.78	31.13	27	9171	19314	90599935
Disease progression	43.99	31.13	66	9132	156549	90462700
Neutropenia	42.08	31.13	79	9119	224825	90394424
Eastern Cooperative Oncology Group performance status worsened	41.68	31.13	13	9185	1926	90617323
Pain	41.50	31.13	25	9173	996316	89622933
Sepsis	41.16	31.13	69	9129	179745	90439504
Bacillus infection	41.11	31.13	11	9187	948	90618301
Tubulointerstitial nephritis	39.09	31.13	27	9171	25316	90593933
Headache	38.28	31.13	20	9178	862726	89756523
Skin toxicity	38.22	31.13	17	9181	6762	90612487
Enterocolitis	36.84	31.13	19	9179	10471	90608778
Non-small cell lung cancer recurrent	36.83	31.13	7	9191	125	90619124
Drug ineffective	34.32	31.13	55	9143	1384243	89235006
Encephalitis	32.97	31.13	18	9180	11116	90608133
Immune-mediated cholangitis	31.36	31.13	7	9191	282	90618967

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Radiation pneumonitis	2127.39	22.65	431	16380	2502	42602022
Malignant neoplasm progression	1066.51	22.65	611	16200	107789	42496735
Pneumonitis	733.70	22.65	348	16463	41370	42563154
Death	547.21	22.65	788	16023	470397	42134127
Interstitial lung disease	456.28	22.65	318	16493	78144	42526380
Immune-mediated enterocolitis	417.05	22.65	134	16677	5543	42598981
Metastases to central nervous system	348.87	22.65	137	16674	10218	42594306
Neutrophil count decreased	326.83	22.65	239	16572	63176	42541348
Immune-mediated hepatic disorder	263.65	22.65	78	16733	2436	42602088
Myelosuppression	218.49	22.65	157	16654	40304	42564220
Myocarditis	212.73	22.65	117	16694	18821	42585703
Cholangitis	201.95	22.65	94	16717	10633	42593891
Immune-mediated hepatitis	185.87	22.65	66	16745	3708	42600816
Colitis	179.68	22.65	148	16663	46424	42558100
Eastern Cooperative Oncology Group performance status worsened	173.69	22.65	49	16762	1287	42603237
Immune-mediated myocarditis	171.64	22.65	54	16757	2080	42602444
Pulmonary toxicity	160.29	22.65	75	16736	8580	42595944
Hypothyroidism	136.49	22.65	108	16703	31976	42572548
Adrenal insufficiency	134.31	22.65	87	16724	18837	42585687
Non-small cell lung cancer recurrent	129.83	22.65	23	16788	53	42604471
Liver disorder	126.41	22.65	113	16698	39531	42564993
Cytokine release syndrome	120.84	22.65	116	16695	44411	42560113
Immune-mediated lung disease	120.60	22.65	47	16764	3426	42601098
Myositis	112.06	22.65	71	16740	14795	42589729
Hepatic function abnormal	111.85	22.65	119	16692	51448	42553076
Liver carcinoma ruptured	94.44	22.65	22	16789	260	42604264
Immune-mediated dermatitis	93.51	22.65	30	16781	1231	42603293
Drug interaction	88.54	22.65	4	16807	266995	42337529
Biliary tract infection	88.46	22.65	26	16785	792	42603732
Tumour hyperprogression	87.18	22.65	19	16792	162	42604362
Lung disorder	82.37	22.65	98	16713	47825	42556699
Febrile neutropenia	81.83	22.65	207	16604	185496	42419028
Hypopituitarism	80.35	22.65	33	16778	2758	42601766
Hyperthyroidism	73.56	22.65	54	16757	14287	42590237
Immune thrombocytopenia	73.32	22.65	49	16762	11167	42593357
Metastases to adrenals	72.72	22.65	24	16787	1078	42603446
Metastases to bone	72.01	22.65	54	16757	14755	42589769
Oesophagitis	68.42	22.65	53	16758	15194	42589330
Adrenocorticotropic hormone deficiency	67.60	22.65	24	16787	1346	42603178
Platelet count decreased	65.76	22.65	159	16652	138422	42466102
Drug-induced liver injury	63.67	22.65	77	16734	38196	42566328
Hypophysitis	61.70	22.65	28	16783	2983	42601541
Enterocolitis	61.61	22.65	42	16769	9887	42594637
Enterocolitis infectious	58.97	22.65	24	16787	1959	42602565
Fulminant type 1 diabetes mellitus	56.35	22.65	21	16790	1353	42603171
Immune-mediated adrenal insuficiency	56.28	22.65	18	16793	731	42603793
Drug ineffective	53.70	22.65	105	16706	630092	41974432
Metastases to liver	52.91	22.65	47	16764	16279	42588245
Encephalitis autoimmune	52.68	22.65	20	16791	1357	42603167
Haematotoxicity	51.07	22.65	39	16772	10946	42593578
Metastases to lymph nodes	48.59	22.65	30	16781	5968	42598556
Gastrointestinal toxicity	45.79	22.65	25	16786	3954	42600570
Thyroiditis	44.79	22.65	23	16788	3213	42601311
Immune-mediated hypophysitis	44.04	22.65	13	16798	402	42604122
Myasthenia gravis	43.65	22.65	42	16769	16095	42588429
Thrombocytopenia	42.68	22.65	168	16643	190111	42414413
Pneumothorax	41.84	22.65	49	16762	23494	42581030
Type 1 diabetes mellitus	40.82	22.65	26	16785	5461	42599063
Immune-mediated adverse reaction	40.15	22.65	15	16796	973	42603551
Metastases to lung	39.25	22.65	34	16777	11390	42593134
Fall	39.05	22.65	22	16789	234498	42370026
Pleural effusion	38.28	22.65	104	16707	97062	42507462
Pulmonary radiation injury	38.22	22.65	8	16803	55	42604469
Pain in extremity	37.52	22.65	7	16804	150597	42453927
Diffuse uveal melanocytic proliferation	35.95	22.65	6	16805	8	42604516
Headache	35.02	22.65	26	16785	239343	42365181
Adrenal disorder	33.84	22.65	14	16797	1191	42603333
Immune-mediated pancreatitis	33.55	22.65	10	16801	320	42604204
Immune-mediated myositis	33.36	22.65	20	16791	3773	42600751
Immune-mediated hypothyroidism	33.09	22.65	14	16797	1260	42603264
Anxiety	32.98	22.65	4	16807	118556	42485968
Immune-mediated nephritis	32.97	22.65	12	16799	723	42603801
Immune-mediated cholangitis	32.83	22.65	11	16800	518	42604006
Pain	32.82	22.65	29	16782	244819	42359705
Lichenoid keratosis	32.62	22.65	20	16791	3930	42600594
Haemoptysis	32.23	22.65	62	16749	46105	42558419
Somnolence	32.21	22.65	8	16803	141097	42463427
Blood thyroid stimulating hormone decreased	30.68	22.65	16	16795	2307	42602217
Immune-mediated encephalitis	30.66	22.65	11	16800	636	42603888
Pneumonia bacterial	30.13	22.65	34	16777	15658	42588866
Pneumonia	29.84	22.65	275	16536	421874	42182650
Pyrexia	29.53	22.65	260	16551	393782	42210742
Paraneoplastic neurological syndrome	29.16	22.65	7	16804	95	42604429
Tumour pseudoprogression	28.82	22.65	12	16799	1038	42603486
Thyroxine free abnormal	28.38	22.65	5	16806	11	42604513
Protein induced by vitamin K absence or antagonist II increased	27.87	22.65	6	16805	48	42604476
Disease progression	27.59	22.65	121	16690	143535	42460989
Pancreatic enzymes increased	27.31	22.65	11	16800	874	42603650
Insomnia	26.41	22.65	7	16804	118246	42486278
Skin disorder	26.40	22.65	33	16778	16911	42587613
Dizziness	26.26	22.65	36	16775	249218	42355306
Hepatic infection	25.25	22.65	10	16801	760	42603764
Liver function test increased	25.06	22.65	35	16776	19963	42584561
Lymphoma transformation	25.04	22.65	9	16802	523	42604001
Hypothalamo-pituitary disorder	25.00	22.65	11	16800	1089	42603435
Oropharyngeal oedema	24.37	22.65	6	16805	91	42604433
Tumour marker increased	24.36	22.65	10	16801	834	42603690
Cholangitis acute	24.29	22.65	11	16800	1166	42603358
Thrombophlebitis migrans	24.18	22.65	8	16803	362	42604162
Autoimmune hepatitis	23.97	22.65	19	16792	5626	42598898
Overdose	23.95	22.65	6	16805	105258	42499266
Liver abscess	23.88	22.65	18	16793	4952	42599572
Muscle spasms	23.69	22.65	3	16808	86041	42518483
Seizure	23.62	22.65	9	16802	120552	42483972
Metastases to pleura	23.54	22.65	9	16802	622	42603902
Bradycardia	23.49	22.65	3	16808	85481	42519043
Diabetic ketoacidosis	23.47	22.65	36	16775	22331	42582193
Condition aggravated	23.34	22.65	42	16769	260712	42343812
Hepatitis	23.29	22.65	40	16771	27260	42577264
Nasopharyngitis	22.95	22.65	3	16808	83993	42520531

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Radiation pneumonitis	2851.29	24.42	533	22483	4003	110562280
Malignant neoplasm progression	1413.91	24.42	699	22317	173868	110392415
Pneumonitis	892.34	24.42	395	22621	76136	110490147
Interstitial lung disease	613.92	24.42	374	22642	138960	110427323
Death	592.45	24.42	725	22291	698144	109868139
Immune-mediated enterocolitis	547.51	24.42	163	22853	10022	110556261
Neutrophil count decreased	515.61	24.42	318	22698	120623	110445660
Cholangitis	406.79	24.42	146	22870	16189	110550094
Metastases to central nervous system	404.52	24.42	159	22857	22658	110543625
Immune-mediated hepatic disorder	383.43	24.42	103	22913	4347	110561936
Myelosuppression	324.85	24.42	217	22799	94123	110472160
Myocarditis	311.17	24.42	143	22873	29912	110536371
Immune-mediated hepatitis	282.32	24.42	89	22927	6622	110559661
Colitis	269.96	24.42	200	22816	102123	110464160
Hypothyroidism	268.66	24.42	175	22841	72724	110493559
Biliary tract infection	263.04	24.42	63	22953	1661	110564622
Immune-mediated myocarditis	250.45	24.42	70	22946	3428	110562855
Cytokine release syndrome	221.17	24.42	153	22863	70153	110496130
Hepatic function abnormal	214.35	24.42	165	22851	89130	110477153
Eastern Cooperative Oncology Group performance status worsened	206.12	24.42	58	22958	2911	110563372
Febrile neutropenia	202.16	24.42	287	22729	316480	110249803
Pulmonary toxicity	191.71	24.42	87	22929	17659	110548624
Adrenal insufficiency	189.35	24.42	115	22901	42275	110524008
Platelet count decreased	185.59	24.42	234	22782	230209	110336074
Immune-mediated lung disease	184.93	24.42	61	22955	5242	110561041
Non-small cell lung cancer recurrent	172.56	24.42	31	22985	179	110566104
Liver carcinoma ruptured	134.39	24.42	27	22989	303	110565980
Tumour hyperprogression	131.60	24.42	27	22989	339	110565944
Immune-mediated dermatitis	124.53	24.42	37	22979	2253	110564030
Hyperthyroidism	122.03	24.42	76	22940	29185	110537098
Thyroiditis	120.64	24.42	47	22969	6526	110559757
Drug-induced liver injury	117.98	24.42	135	22881	119932	110446351
Metastases to bone	114.72	24.42	75	22941	31297	110534986
Myositis	112.84	24.42	74	22942	31042	110535241
Immune thrombocytopenia	110.76	24.42	65	22951	22429	110543854
Liver disorder	107.39	24.42	140	22876	142103	110424180
Pyrexia	107.28	24.42	419	22597	897846	109668437
Pain	107.10	24.42	33	22983	954922	109611361
Pleural effusion	102.96	24.42	154	22862	177555	110388728
Hypopituitarism	100.89	24.42	37	22979	4353	110561930
Adrenocorticotropic hormone deficiency	100.40	24.42	31	22985	2151	110564132
Myasthenia gravis	100.27	24.42	60	22956	21451	110544832
Liver abscess	99.88	24.42	43	22973	7696	110558587
Oesophagitis	91.43	24.42	63	22953	28652	110537631
Hypophysitis	89.86	24.42	36	22980	5379	110560904
Metastases to adrenals	87.60	24.42	26	22990	1577	110564706
Headache	86.24	24.42	38	22978	882339	109683944
Drug interaction	84.13	24.42	5	23011	500178	110066105
Thrombocytopenia	83.92	24.42	208	22808	348677	110217606
Metastases to liver	81.82	24.42	64	22952	35322	110530961
Fulminant type 1 diabetes mellitus	81.66	24.42	27	22989	2336	110563947
Anaemia	81.04	24.42	274	22742	546812	110019471
Immune-mediated hypothyroidism	80.30	24.42	28	22988	2847	110563436
Cholangitis infective	79.77	24.42	21	22995	818	110565465
Metastases to lung	79.14	24.42	53	22963	23010	110543273
Immune-mediated myositis	78.62	24.42	34	22982	6152	110560131
Encephalitis autoimmune	78.36	24.42	29	22987	3499	110562784
Haematotoxicity	76.10	24.42	50	22966	21032	110545251
Bile duct stenosis	74.50	24.42	26	22990	2650	110563633
Enterocolitis	73.45	24.42	47	22969	18902	110547381
Immune-mediated adverse reaction	73.38	24.42	23	22993	1677	110564606
Joint swelling	72.76	24.42	5	23011	442840	110123443
Pemphigoid	69.34	24.42	46	22970	19661	110546622
Immune-mediated cholangitis	69.30	24.42	19	22997	865	110565418
Immune-mediated adrenal insuficiency	68.23	24.42	22	22994	1758	110564525
Drug hypersensitivity	66.92	24.42	8	23008	454082	110112201
Pain in extremity	66.13	24.42	11	23005	487107	110079176
Nasopharyngitis	66.12	24.42	4	23012	394357	110171926
Abdominal discomfort	66.02	24.42	4	23012	393854	110172429
Type 1 diabetes mellitus	63.41	24.42	33	22983	9014	110557269
Thrombophlebitis migrans	62.37	24.42	17	22999	757	110565526
Embolism	62.14	24.42	40	22976	16249	110550034
Radiation interaction	61.91	24.42	11	23005	59	110566224
Pneumothorax	61.13	24.42	54	22962	35231	110531052
Lichenoid keratosis	59.03	24.42	28	22988	6274	110560009
Sepsis	58.47	24.42	175	22841	327171	110239112
Gastrointestinal toxicity	56.95	24.42	33	22983	11115	110555168
Peripheral swelling	55.10	24.42	9	23007	404025	110162258
Drug ineffective	55.08	24.42	150	22866	1520390	109045893
Dizziness	53.95	24.42	40	22976	698153	109868130
Pulmonary radiation injury	53.75	24.42	10	23006	72	110566211
Metastases to lymph nodes	52.67	24.42	35	22981	14997	110551286
Weight increased	51.64	24.42	12	23004	419632	110146651
Drug intolerance	51.28	24.42	11	23005	406501	110159782
Bacterial abdominal infection	51.18	24.42	9	23007	45	110566238
Anxiety	51.02	24.42	6	23010	345072	110221211
Immune-mediated nephritis	50.40	24.42	16	23000	1216	110565067
Encephalitis	50.00	24.42	37	22979	18802	110547481
Hepatic infection	49.57	24.42	16	23000	1283	110565000
Depression	48.22	24.42	5	23011	317330	110248953
Arthropathy	47.93	24.42	3	23013	287519	110278764
Pneumonia	47.88	24.42	329	22687	876385	109689898
Diabetic ketoacidosis	47.68	24.42	51	22965	42007	110524276
Immune-mediated pancreatitis	45.10	24.42	13	23003	711	110565572
Cytopenia	44.19	24.42	42	22974	30074	110536209
Immune-mediated encephalitis	42.74	24.42	14	23002	1176	110565107
Organising pneumonia	42.42	24.42	30	22986	14213	110552070
Product use issue	42.36	24.42	7	23009	311688	110254595
Arterial intramural haematoma	42.33	24.42	10	23006	248	110566035
Immune-mediated hypophysitis	41.21	24.42	13	23003	968	110565315
Pneumonia bacterial	41.18	24.42	38	22978	26223	110540060
Respiratory failure	40.21	24.42	117	22899	215215	110351068
Haemoptysis	40.08	24.42	61	22955	71293	110494990
Nephritis	39.12	24.42	21	22995	6105	110560178
Tumour pseudoprogression	38.54	24.42	14	23002	1602	110564681
Superior vena cava syndrome	37.22	24.42	13	23003	1328	110564955
Immune-mediated arthritis	37.14	24.42	11	23005	662	110565621
Neuropathy peripheral	36.98	24.42	101	22915	179176	110387107
Protein induced by vitamin K absence or antagonist II increased	36.98	24.42	7	23009	56	110566227
Cholangitis acute	36.24	24.42	14	23002	1899	110564384
Neutropenia	36.08	24.42	164	22852	374456	110191827
Immune-mediated thyroiditis	35.79	24.42	12	23004	1084	110565199
Paraneoplastic neurological syndrome	34.95	24.42	8	23008	172	110566111
Autoimmune hepatitis	34.70	24.42	27	22989	14777	110551506
Fall	34.55	24.42	45	22971	603437	109962846
Tubulointerstitial nephritis	34.22	24.42	49	22967	54235	110512048
Wheezing	34.08	24.42	6	23010	255224	110311059
Abdominal pain upper	34.06	24.42	15	23001	349096	110217187
Lymphoma transformation	33.89	24.42	10	23006	594	110565689
Cholangitis sclerosing	33.81	24.42	16	23000	3566	110562717
Urinary tract obstruction	33.77	24.42	18	22998	5159	110561124
Lung disorder	32.81	24.42	97	22919	179950	110386333
Hypersensitivity	32.67	24.42	22	22994	403976	110162307
Pericardial effusion	32.25	24.42	49	22967	57168	110509115
Diffuse uveal melanocytic proliferation	31.90	24.42	5	23011	10	110566273
Immune-mediated renal disorder	31.80	24.42	10	23006	737	110565546
Malignant pleural effusion	31.78	24.42	16	23000	4077	110562206
Polyneuropathy	31.42	24.42	36	22980	31976	110534307
Enterocolitis infectious	31.34	24.42	15	23001	3429	110562854
Small intestinal obstruction	31.23	24.42	36	22980	32177	110534106
Carcinoembryonic antigen increased	30.98	24.42	14	23002	2810	110563473
Arthralgia	30.33	24.42	74	22942	779558	109786725
Overdose	30.14	24.42	6	23010	233788	110332495
Cerebral infarction	30.08	24.42	45	22971	51793	110514490
Radiation oesophagitis	30.03	24.42	10	23006	884	110565399
Oesophagomediastinal fistula	29.76	24.42	5	23011	18	110566265
Hepatic failure	29.45	24.42	52	22964	68687	110497596
Erythema	29.26	24.42	12	23004	291435	110274848
Condition aggravated	29.17	24.42	69	22947	734767	109831516
Renal colic	29.07	24.42	14	23002	3244	110563039
Pemphigus	28.74	24.42	5	23011	214565	110351718
Somnolence	28.67	24.42	13	23003	297436	110268847
Insomnia	28.67	24.42	20	22996	360570	110205713
Metastases to pleura	28.40	24.42	12	23004	2051	110564232
Metastasis	28.36	24.42	19	22997	8248	110558035
Therapeutic product effect incomplete	28.32	24.42	6	23010	223799	110342484
Diarrhoea	28.17	24.42	361	22655	1139144	109427139
Lower respiratory tract infection	27.88	24.42	8	23008	243098	110323185
Bacillus infection	27.72	24.42	11	23005	1603	110564680
Skin disorder	27.44	24.42	39	22977	42874	110523409
Lipase increased	27.32	24.42	26	22990	18646	110547637
Helicobacter infection	27.27	24.42	3	23013	181874	110384409
Autoimmune nephritis	27.03	24.42	9	23007	795	110565488
Blood pressure increased	26.99	24.42	10	23006	258363	110307920
Intentional product use issue	26.92	24.42	9	23007	247897	110318386
Autoimmune hypothyroidism	26.67	24.42	8	23008	503	110565780
Dyspepsia	26.59	24.42	4	23012	190961	110375322
Adrenal disorder	26.50	24.42	12	23004	2420	110563863
Duodenal ulcer perforation	26.47	24.42	3	23013	177697	110388586
Hepatic encephalopathy	26.43	24.42	31	22985	28225	110538058
White blood cell count decreased	26.37	24.42	106	22910	229284	110336999
Asthma	25.63	24.42	10	23006	250281	110316002
Memory impairment	25.50	24.42	5	23011	196939	110369344
Psoriatic arthropathy	25.46	24.42	5	23011	196756	110369527
Tumour haemorrhage	25.40	24.42	15	23001	5230	110561053
Neoplasm progression	25.30	24.42	47	22969	64548	110501735
Musculoskeletal pain	25.10	24.42	4	23012	183019	110383264
Stress cardiomyopathy	25.03	24.42	23	22993	15783	110550500
Enteritis	24.89	24.42	25	22991	19131	110547152
Hypothalamo-pituitary disorder	24.70	24.42	12	23004	2834	110563449
Feeling abnormal	24.67	24.42	4	23012	180707	110385576
Tumour rupture	24.66	24.42	8	23008	652	110565631

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FF03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
MeSH PA	D000074322	Antineoplastic Agents, Immunological
MeSH PA	D000970	Antineoplastic Agents
FDA CS	M0001357	Antibodies, Monoclonal
FDA MoA	N0000193336	Programmed Death Ligand-1-directed Antibody Interactions
FDA MoA	N0000193337	Programmed Death Ligand-1 Antagonists
FDA EPC	N0000193338	Programmed Death Ligand-1 Blocker
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:64951	anti-HBV agent
CHEBI has role	CHEBI:233423	antifibrotic agent

Related Drugs by ATC class:

L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors 11 drugs

atezolizumabavelumabcemiplimabdostarlimabnivolumabpembrolizumabretifanlimabserplulimabsugemalimabtislelizumabtoripalimab

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Transitional cell carcinoma	indication	27090000	DOID:2671
Liver cell carcinoma	indication	109841003	DOID:684
Small cell carcinoma of lung	indication	254632001	DOID:5409
Non-small cell lung cancer	indication	254637007	DOID:3908
Extensive stage primary small cell carcinoma of lung	indication
Metastatic carcinoma to biliary tract	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Programmed cell death 1 ligand 1	CD molecules	Q9NZQ7	PD1L1_HUMAN	ANTIBODY BINDING				UNKNOWN	DRUG LABEL

External reference:

ID	Source
28X28X9OKV	UNII
4036653	VANDF
C4055109	UMLSCUI
CHEBI:755270	CHEBI
CHEMBL3301587	ChEMBL_ID
DB11714	DRUGBANK_ID
D10808	KEGG_DRUG
10010	INN_ID
C000613593	MESH_SUPPLEMENTAL_RECORD_UI
7985	IUPHAR_LIGAND_ID
735230005	SNOMEDCT_US
763588004	SNOMEDCT_US
256648	MMSL
32681	MMSL
d08576	MMSL
017200	NDDF
1919503	RXNORM

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
IMFINZI	HUMAN PRESCRIPTION DRUG LABEL	1	0310-4500	INJECTION, SOLUTION	120 mg	INTRAVENOUS	BLA	24 sections
IMFINZI	HUMAN PRESCRIPTION DRUG LABEL	1	0310-4611	INJECTION, SOLUTION	500 mg	INTRAVENOUS	BLA	24 sections